Ptc Therapeutics PTCT Institutional Ownership

Ptc Therapeutics, Inc. (NASDAQ:PTCT) showed up in the 13F filings of 382 institutional investors as of June 2026.

• Their combined ownership stood at 121.7% of outstanding shares in June 2026, down from 124.5% in March 2026.
• Their total shares held in PTCT increased 16.27% quarter over quarter, and separately, investors owning Ptc Therapeutics increased 34.51% from a year ago.
• Of these 382 funds, 218 grew their exposure to Ptc Therapeutics, 111 cut back, and 53 maintained positions.
• In total, institutional investors held 101.06Mn shares in Ptc Therapeutics as of June 2026, up by 14.14Mn shares quarter on quarter, and up 21.71Mn shares year over year.
• BlackRock, Inc. holds the largest position in PTCT at 13.96Mn shares as of June 30, 2026, or 16.82% of shares outstanding.
• The most significant purchases of PTCT for the quarter ending June 2026 came from Jupiter Topco LLC (7.24Mn), WESTFIELD CAPITAL MANAGEMENT CO LP (1.96Mn), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.72Mn), FULLER & THALER ASSET MANAGEMENT, INC. (1.16Mn), BlackRock, Inc. (1.02Mn).
• Leading sellers of Ptc Therapeutics shares for the quarter ending June 2026 were UBS Group AG (1.1Mn), ARMISTICE CAPITAL, LLC (1.0Mn), Toronto Dominion Bank (860.12K), BNP PARIBAS FINANCIAL MARKETS (541.76K), BALYASNY ASSET MANAGEMENT L.P. (439.96K).
• Business Quant data shows the 10 biggest positions in Ptc Therapeutics as of June 2026 are held by BlackRock, Inc. (13.96Mn), RTW INVESTMENTS, LP (7.75Mn), Jupiter Topco LLC (7.24Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (4.93Mn), State Street Corp (4.6Mn), WELLINGTON MANAGEMENT GROUP LLP (4.13Mn), VANGUARD CAPITAL MANAGEMENT LLC (3.74Mn), GEODE CAPITAL MANAGEMENT, LLC (2.21Mn), Toronto Dominion Bank (2.17Mn), WESTFIELD CAPITAL MANAGEMENT CO LP (1.96Mn).